Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study.

"Conflict of interest statement: Lars Eriksson (Principal Investigator) has participated in clinical trials by Janssen, EliLilly, and AstraZeneca; and given lectures and participated in advisory boards for Janssen, BMS, EliLilly, and AstraZeneca. Andreas Carlborg is a consultant to and has participated in clinical trials by AstraZeneca; and given lectures for Wyeth. Teresa Hallerbäck and Leif Jørgensen are employees of AstraZeneca.: This manuscript was prepared in line with guidelines established by the International Committee of Medical Journal Editors (ICMJE) and published in its Uniform Requirements of Manuscripts Submitted to Biomedical Journals."

"Funding: Dr Graz.yna Söderbom, Klipspringer AB, rovided medical writing support funded by AstraZeneca. This study was sponsored by AstraZeneca."

"The study protocol was reviewed and approved by the Regional Ethics Committee in Gothenburg, Sweden. The study [ClinicalTrials.gov identifier: NCT01214135] was performed in accordance with ethical principles consistent with the Declaration of Helsinki, International Conference on Harmonisation of Good Clinical Practice (ICH GCPs) and the applicable legislation on noninterventional studies."